Barclays lowered the firm’s price target on Orchestra BioMed (OBIO) to $11 from $12 and keeps an Overweight rating on the shares. The firm says the company highlighted clinical and strategic achievements when reporting Q3.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OBIO:
- Orchestra BioMed reports Q3 EPS (40c), consensus (43c)
- Orchestra BioMed files to sell 8.03M shares of common stock for holders
- Orchestra BioMed Secures $147M for Therapy Advancements
- Orchestra BioMed Announces Strategic Agreement with Terumo
- Orchestra BioMed, Terumo enter new $30M Virtue SAB agreements